Cancer Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change

Dec 2020| TBR1163A| TBRC (Publisher)

Report Highlights

Cancer Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change

Including: 1) By Monoclonal Antibody Therapies: Bevacizumab (Avastin); Rituximab (Rituxan); Trastuzumab (Herceptin); Cetuximab (Erbitux); Panitumumab (Vectibix); Others
2) By Application: Breast Cancer; Blood Cancer; Liver Cancer; Brain Cancer; Colorectal Cancer; Others

Covering: Amgen; Bristol Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genmab AS

Cancer Monoclonal Antibodies (mAbs) Global Market Report 2020-30: COVID-19 Growth And Change from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global cancer monoclonal antibodies (mabs) market.

This report focuses on cancer monoclonal antibodies (mabs) market which is experiencing strong growth. The report gives a guide to the cancer monoclonal antibodies (mabs) market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Description:
Where is the largest and fastest growing market for the cancer monoclonal antibodies (mabs)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Cancer Monoclonal Antibodies (mAbs) market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider cancer monoclonal antibodies (mabs) market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the Covid 19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of Covid 19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The cancer monoclonal antibodies (mabs) market section of the report gives context. It compares the cancer monoclonal antibodies (mabs) market with other segments of the cancer monoclonal antibodies (mabs) market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, cancer monoclonal antibodies (mabs) indicators comparison.

Scope

Markets Covered: 1) By Monoclonal Antibody Therapies: Bevacizumab (Avastin); Rituximab (Rituxan); Trastuzumab (Herceptin); Cetuximab (Erbitux); Panitumumab (Vectibix); Others
2) By Application: Breast Cancer; Blood Cancer; Liver Cancer; Brain Cancer; Colorectal Cancer; Others

Companies Mentioned: Amgen; Bristol Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genmab AS

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

  • Table 1 : Global Historic Market Growth, 2015-2019, $ Billion
  • Table 2 : Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 3 : Global Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 4 : Global Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 5 : Global Cancer Monoclonal Antibodies (mAbs) Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 6 : Global Cancer Monoclonal Antibodies (mAbs) Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 7 : Asia-Pacific, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 8 : China, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 9 : India, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 10 : Japan, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 11 : Australia, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 12 : Indonesia, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 13 : South Korea, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 14 : Western Europe, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 15 : UK, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 16 : Germany, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 17 : France, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 18 : Eastern Europe, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 19 : Russia, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 20 : North America, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 21 : USA, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 22 : South America, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 23 : Brazil, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 24 : Middle East, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 25 : Africa, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Table 26 : Amgen Financial Performance
  • Table 27 : Bristol Myers Squibb Company Financial Performance
  • Table 28 : Eli Lilly and Company Financial Performance
  • Table 29 : F. Hoffmann-La Roche Ltd Financial Performance
  • Table 30 : Genmab AS Financial Performance
  • Figure 1 : Global Historic Market Growth, 2015-2019, $ Billion
  • Figure 2 : Global Forecast Market Growth, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 3 : Global Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 4 : Global Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 5 : Global Cancer Monoclonal Antibodies (mAbs) Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 6 : Global Cancer Monoclonal Antibodies (mAbs) Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 7 : Asia-Pacific, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 8 : China, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 9 : India, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 10 : Japan, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 11 : Australia, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 12 : Indonesia, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 13 : South Korea, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 14 : Western Europe, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 15 : UK, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 16 : Germany, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 17 : France, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 18 : Eastern Europe, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 19 : Russia, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 20 : North America, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 21 : USA, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 22 : South America, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 23 : Brazil, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 24 : Middle East, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 25 : Africa, Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Figure 26 : Amgen Financial Performance
  • Figure 27 : Bristol Myers Squibb Company Financial Performance
  • Figure 28 : Eli Lilly and Company Financial Performance
  • Figure 29 : F. Hoffmann-La Roche Ltd Financial Performance
  • Figure 30 : Genmab AS Financial Performance

The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has over 50 research professionals at its offices in India, the UK and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report